SOLIRIS

•Caution should be exercised in patients with history of infection, fever, any allergy, who are taking other medications, children, during pregnancy and breastfeeding. Avoid contact with people who have infections. Immunize patients with meningococcal vaccine two weeks prior to the treatment, as eculizumab increases the risk of life-threatening and fatal meningococcal infections.​​​‍​​‍​​​​‍​​‍‍ Children should also be vaccinated against Streptococcus pneumoniae and Hemophilus influenza type b (Hib). • Because of the risk of meningococcal infections, eculizumab is made available only to prescribers who enroll in Risk Evaluation and Mitigation Strategy (REMS) program. The physician should educate the patient about the risk of meningococcal infection following use of the drug. The patient should be followed up and carry a card indicating his/her risk for meningococcal infection till about three months following the completion of treatment. Inform your doctor about the use of other medications before the administration of eculizumab to avoid serious side effects.